Publications by authors named "H Neuwirt"
Background: Lu PSMA therapy is increasingly used for metastatic castration-resistant prostate cancer (mCRPC) treatment. However, data on its efficacy and safety in patients previously treated with Ra remain limited.
Methods: This retrospective, multicenter study evaluated 233 mCRPC patients treated with Lu PSMA at 5 European centers.
Article Synopsis
- The study investigates the metabolic profiles in patients suspected of prostate cancer, focusing on differentiating clinically significant (csPCa) from clinically insignificant (ciPCa) and benign cases using serum samples.
- A 22-metabolite panel was identified, which improves the discrimination of csPCa when combined with traditional clinical parameters like age and PSA levels, achieving an AUC of 0.84.
- This research suggests that the identified metabolites, particularly ornithine and dimethylglycine, could serve as biomarkers to reduce unnecessary biopsies and identify potential treatment targets for prostate cancer.
: Anemia is a frequent multifactorial co-morbidity in end-stage kidney disease (ESKD) associated with morbidity and poor QoL. Apart from insufficient erythropoietin formation, iron deficiency (ID) contributes to anemia development. Identifying patients in need of iron supplementation with current ID definitions is difficult since no good biomarker is available to detect actual iron needs.
View Article and Find Full Text PDFBackground: Assessments, such as summative structured examinations, aim to verify whether students have acquired the necessary competencies. It is important to familiarize students with the examination format prior to the assessment to ensure that true competency is measured. However, it is unclear whether students can demonstrate their true potential or possibly perform less effectively due to the unfamiliar examination format.
View Article and Find Full Text PDFArticle Synopsis
- Two randomized trials have established that triplet therapy (androgen deprivation therapy, ARPI, and docetaxel) provides better survival rates compared to doublet therapy (ADT and docetaxel) for patients with metastatic hormone-sensitive prostate cancer.
- A real-world analysis involving 97 mHSPC patients from various Austrian centers was conducted, tracking treatment responses and clinical parameters, while certain guideline-based treatments were underutilized in a significant percentage of the patients.
- Findings showed that patients who started ARPI after chemotherapy had better treatment responses, while 61.9% experienced adverse events, yet all patients had a notable decline in PSA levels, indicating treatment effectiveness.